Extended-Duration MK-8591-Eluting Implant as a Candidate for HIV Treatment and Prevention-Reference-Cited by-同舟云学术

Extended-Duration MK-8591-Eluting Implant as a Candidate for HIV Treatment and Prevention

Published:2018-10 Issue:10 Volume:62 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Barrett Stephanie E.¹^ORCID,Teller Ryan S.¹,Forster Seth P.¹,Li Li¹,Mackey Megan A.¹,Skomski Daniel¹,Yang Zhen¹,Fillgrove Kerry L.²,Doto Gregory J.³,Wood Sandra L.³,Lebron Jose³,Grobler Jay A.⁴,Sanchez Rosa I.²,Liu Zhen¹,Lu Bing²,Niu Tao²,Sun Li²,Gindy Marian E.¹

Affiliation:

1. Pharmaceutical Sciences, Merck & Co., Inc., West Point, Pennsylvania, USA

2. Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., West Point, Pennsylvania, USA

3. Safety Assessment and Laboratory Animals Research, Merck & Co., Inc., West Point, Pennsylvania, USA

4. Infectious Diseases Discovery Research, Merck & Co., Inc., West Point, Pennsylvania, USA

Abstract

Regimen adherence remains a major hurdle to the success of daily oral drug regimens for the treatment and prevention of human immunodeficiency virus (HIV) infection. Long-acting drug formulations requiring less-frequent dosing offer an opportunity to improve adherence and allow for more forgiving options with regard to missed doses.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01058-18

Reference36 articles.

1. HIV-1 Protease Inhibitors

2. Treatment for Adult HIV Infection

3. UNAIDS. 2017. Ending AIDS: progress towards the 90-90–90 targets. Joint United Nations Programme on HIV/AIDS (UNAIDS) Geneva Switzerland. http://www.unaids.org/sites/default/files/media_asset/Global_AIDS_update_2017_en.pdf.

4. UNAIDS. 2017. Fact sheet–latest statistics on the status of the AIDS epidemic. Joint United Nations Programme on HIV/AIDS (UNAIDS) Geneva Switzerland. http://www.unaids.org/en/resources/fact-sheet.

5. Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men

Cited by 111 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antiretroviral (ARV) Properties Dictate Long-Acting Release and Tissue Partitioning Behaviors in Multidrug Subcutaneous Implants;ACS Biomaterials Science & Engineering;2024-09-04

2. Manufacture, characterization, and elucidation of drug release mechanisms of etonogestrel implants based on ethylene vinyl acetate;Journal of Pharmaceutical Sciences;2024-09

3. Modeling of HIV‐1 prophylactic efficacy and toxicity with islatravir shows non‐superiority for oral dosing, but promise as a subcutaneous implant;CPT: Pharmacometrics & Systems Pharmacology;2024-08-20

4. Development of a Biocatalytic Aerobic Oxidation for the Manufacturing Route to Islatravir;Organic Process Research & Development;2024-08-14

5. Defining blood hematology reference values in female pig‐tailed macaques (Macaca nemestrina) using the Isolation Forest algorithm;Journal of Medical Primatology;2024-07-08